Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Kampo Medicine May Ease Age
- The quiet power of pets: Can pets really support a family’s mental health and wellbeing? | ABS
- Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance
- Hanmi signs record $2.3 bn obesity drug licensing deal
- Former Razorbacks’ All-SEC Safety Up By Arizona Cardinals Following Workout
- National Waffle Day: Easy Ways to Add More Nutrition to Waffles
- ‘No public health outbreak’: Colbert Co. school officials address student seizures
- Deprescribing: The long road off antidepressants
Browsing: over
Novo Nordisk sued Eli Lilly on Tuesday, accusing its rival of misleading consumers by claiming Lilly’s drugs work better than Novo’s competing treatments
Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.
AdventHealth will take over three Denver-area hospitals owned by Intermountain Health, along with their associated clinics, free-standing emergency rooms and urgent care centers
https://p.dw.com/p/5HVXJ The two companies’ diabetes drugs have also become popular for weight lossImage: Jens Kalaene/dpa/picture alliance
Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s
Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly’s advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo’s latest higher-dose Wegovy and Ozempic treatments. Novo is seeking to halt the advertising, require corrective marketing, and recover damages as the companies compete in the growing obesity…
The lawsuit, filed in the U.S. District Court for the District of New Jersey, accuses the competitor of violating both state and federal false advertising and unfair competition laws
The battle of big pharma rages on as Novo Nordisk takes a shot at rival Eli Lilly in a new misleading advertising lawsuit
Novo Nordisk filed a lawsuit against Eli Lilly on Tuesday, alleging that advertising campaigns for Lilly’s obesity drug Zepbound and diabetes drug Mounjaro mislead consumers by using outdated clinical data to suggest those treatments are more effective than Novo’s rival injections
Shop TODAY Beauty Awards: 120 Editor-Tested Products That Made the Cut Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement July 21, 202602:08 $1 Billion up for Grabs as Mega Millions and Powerball Prizes Soar 00:37 Now Playing Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement 02:08 UP NEXT Hundreds Gather to…

